Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BIO-TECHNE Corp (TECH) vs Uber Technologies Inc (UBER) Price & Performance

BIO-TECHNE CorpTrade
Uber Technologies IncTrade

Price performance (Past 24H)

Key statistics

BIO-TECHNE Corp vs Uber Technologies Inc — how do they compare? BIO-TECHNE Corp trades at $72.12 (market cap $11.24B), while Uber Technologies Inc trades at $78.41 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 14.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.

TECHUBER
Market Cap
$11.24B$159.38B
Sector
HealthIndustrials
52-Week High
$72.29$100.10
52-Week Low
$43.31$65.94
Enterprise Value
$11.32B$168.72B
Dividend Yield
0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.

Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.

Uber Technologies Inc

Uber Technologies (UBER) is trading at $75.02, up 6.46% today, with strong technical momentum and bullish moving averages. The company shows robust revenue growth from $31.9B in 2022 to $52.0B in 2025, with net income turning positive since 2023. Recent developments include expansion into autonomous vehicle partnerships and strategic workforce adjustments in HR roles.

Uber presents a compelling growth story with improving profitability and strong analyst support (81.67% buy rating). Key risks include execution challenges in autonomous vehicle deployment and competitive pressures in key markets like India. The consensus price target of $102.88 suggests significant upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH

About Uber Technologies Inc

Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.

Read more on UBER